These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 16722654)
1. Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. Göblyös A; Gao ZG; Brussee J; Connestari R; Santiago SN; Ye K; Ijzerman AP; Jacobson KA J Med Chem; 2006 Jun; 49(11):3354-61. PubMed ID: 16722654 [TBL] [Abstract][Full Text] [Related]
2. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. Gao ZG; Ye K; Göblyös A; Ijzerman AP; Jacobson KA BMC Pharmacol; 2008 Dec; 8():20. PubMed ID: 19077268 [TBL] [Abstract][Full Text] [Related]
3. Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. Kim Y; de Castro S; Gao ZG; Ijzerman AP; Jacobson KA J Med Chem; 2009 Apr; 52(7):2098-108. PubMed ID: 19284749 [TBL] [Abstract][Full Text] [Related]
4. Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Gao ZG; Verzijl D; Zweemer A; Ye K; Göblyös A; Ijzerman AP; Jacobson KA Biochem Pharmacol; 2011 Sep; 82(6):658-68. PubMed ID: 21718691 [TBL] [Abstract][Full Text] [Related]
5. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. Gao ZG; Kim SG; Soltysiak KA; Melman N; IJzerman AP; Jacobson KA Mol Pharmacol; 2002 Jul; 62(1):81-9. PubMed ID: 12065758 [TBL] [Abstract][Full Text] [Related]
6. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. Heitman LH; Göblyös A; Zweemer AM; Bakker R; Mulder-Krieger T; van Veldhoven JP; de Vries H; Brussee J; Ijzerman AP J Med Chem; 2009 Feb; 52(4):926-31. PubMed ID: 19161279 [TBL] [Abstract][Full Text] [Related]
7. Species differences and mechanism of action of A Du L; Gao ZG; Paoletta S; Wan TC; Gizewski ET; Barbour S; van Veldhoven JPD; IJzerman AP; Jacobson KA; Auchampach JA Purinergic Signal; 2018 Mar; 14(1):59-71. PubMed ID: 29170977 [TBL] [Abstract][Full Text] [Related]
8. Lipid Trolling to Optimize A Pradhan B; Pavan M; Fisher CL; Salmaso V; Wan TC; Keyes RF; Rollison N; Suresh RR; Kumar TS; Gao ZG; Smith BC; Auchampach JA; Jacobson KA J Med Chem; 2024 Jul; 67(14):12221-12247. PubMed ID: 38959401 [TBL] [Abstract][Full Text] [Related]
10. Extrahelical Binding Site for a 1 Fisher CL; Pavan M; Salmaso V; Keyes RF; Wan TC; Pradhan B; Gao ZG; Smith BC; Jacobson KA; Auchampach JA Mol Pharmacol; 2024 Feb; 105(3):213-223. PubMed ID: 38182432 [TBL] [Abstract][Full Text] [Related]
11. Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Gao ZG; Van Muijlwijk-Koezen JE; Chen A; Müller CE; Ijzerman AP; Jacobson KA Mol Pharmacol; 2001 Nov; 60(5):1057-63. PubMed ID: 11641434 [TBL] [Abstract][Full Text] [Related]
12. Genetic and functional modulation by agonist MRS5698 and allosteric enhancer LUF6000 at the native A Gao ZG; Chen W; Gao RR; Li J; Tosh DK; Hanover JA; Jacobson KA Purinergic Signal; 2024 Oct; 20(5):559-570. PubMed ID: 38416332 [TBL] [Abstract][Full Text] [Related]